Form 4: Ovid Therapeutics Director Stelios Papadopoulos Acquires 90,000 Stock Options

Director Stelios Papadopoulos of Ovid Therapeutics Inc. reports the acquisition of 90,000 stock options exercisable at $0.49, vesting monthly over three years.

Summary

• Stelios Papadopoulos, a director of Ovid Therapeutics Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 90,000 stock options on March 3, 2025.
• The exercise price of the options is $0.49 per share.
• The options vest in 36 equal monthly installments starting on April 3, 2025, contingent upon continued service.
• The options expire on March 2, 2035.
• Following the transaction, Papadopoulos directly owns 90,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own. The director's acquisition could be seen as a mild positive, indicating confidence.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates